Target Name: FKRP
NCBI ID: G79147
Other Name(s): LGMDR9 | fukutin related protein | LGMD2I | Ribitol 5-phosphate transferase FKRP | MDDGC5 | FKRP_HUMAN | MDC1C | FKTR | Fukutin related protein, transcript variant 1 | FKRP variant 1 | MDDGB5 | Ribitol-5-phosphate transferase | Fukutin related protein, transcript variant 2 | ribitol-5-phosphate transferase | FKRP variant 2 | Fukutin-related protein | MDDGA5

Understanding FKRP: Potential Drug Targets for Various Diseases

FKRP (fluoroalkyl acid peptide), also known as LGMDR9, is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a key regulator of the cell cycle, and has has been implicated in a number of cellular processes that are important for normal development and function.

In recent years, researchers have been interested in FKRP as a potential drug target or biomarker. This is because FKRP has been shown to play a role in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, FKRP has has been shown to be involved in a number of cellular processes that are important for disease development, and may be a useful target for new therapies.

One of the key reasons for the interest in FKRP as a drug target is its role in the regulation of the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate themselves. FKRP is a key regulator of the cell cycle, and has been shown to play a role in the G1 phase of the cell cycle, which is the phase when cells prepare for cell division.

In addition to its role in the cell cycle, FKRP has also been shown to be involved in the regulation of cell adhesion. Cells adhesion is the process by which cells stick together to form tissues and organs. the regulation of cell adhesion, and has been implicated in a number of diseases, including cancer.

In addition to its role in the cell cycle and cell adhesion, FKRP has also been shown to be involved in the regulation of inflammation. Inflammation is a natural response of the immune system to injury or infection. FKRP has been shown to play a role in the regulation of inflammation, and has been implicated in a number of inflammatory diseases, including autoimmune disorders.

In addition to its role in the cell cycle, cell adhesion, and inflammation, FKRP has also been shown to be involved in the regulation of a number of other cellular processes that are important for normal development and function. For example, FKRP has been shown to play a role in the regulation of gene expression, cell signaling, and cellular signaling pathways.

As a potential drug target, FKRP has been shown to be involved in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that inhibiting FKRP can lead to the growth of cancer cells, and that inhibiting FKRP can also lead to the development of neurodegenerative diseases. In addition, FKRP has been shown to be involved in the regulation of a number of diseases that are important for human health, including heart disease, liver disease, and diabetes.

In conclusion, FKRP is a protein that is expressed in various tissues throughout the body, and has been shown to play a role in a number of cellular processes that are important for normal development and function. As a potential drug target, FKRP is of interest due to its role in the regulation of the cell cycle, cell adhesion, inflammation, and other cellular processes that are important for human health. Further research is needed to fully understand the role of FKRP as a drug target, and to develop new treatments for diseases associated with FKRP dysfunction.

Protein Name: Fukutin Related Protein

Functions: Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:29477842, PubMed:31949166, PubMed:27194101). This constitutes the second step in the formation of the ribose 5-phosphate tandem repeat which links the phosphorylated O-mannosyl trisaccharide to the ligand binding moiety composed of repeats of 3-xylosyl-alpha-1,3-glucuronic acid-beta-1 (PubMed:25279699, PubMed:26923585, PubMed:29477842, PubMed:31949166, PubMed:27194101)

More Common Targets

FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P | FMOD | FMR1 | FMR1-AS1 | FMR1NB | FN1 | FN3K | FN3KRP | FNBP1 | FNBP1L | FNBP1P1 | FNBP4 | FNDC1 | FNDC10 | FNDC11 | FNDC3A | FNDC3B | FNDC4 | FNDC5 | FNDC7 | FNDC8 | FNDC9 | FNIP1 | FNIP2 | FNTA | FNTB | FOCAD | Focal Adhesion Kinases (FAK) | Folate Receptor | FOLH1 | FOLH1B | Follicle stimulating hormone | FOLR1 | FOLR2